Propanc Biopharma Closes $4 Million Public Offering to Advance Cancer Stem Cell Therapy Development

Propanc Biopharma, Inc. (NASDAQ: PPCB) has completed a $4 million underwritten public offering, selling 1,000,000 shares of common stock at $4.00 per share. The offering, which closed on August 18, 2025, provides critical funding for the company's development of innovative cancer treatments targeting cancer stem cells. This capital infusion is significant for advancing clinical research in pancreatic, ovarian, and colorectal cancers, where recurrence and metastasis remain major treatment challenges.

The company granted the underwriter a 45-day option to purchase up to 150,000 additional shares, potentially increasing the total proceeds. D. Boral Capital LLC and Craft Capital Management LLC served as book running managers for the offering, with shares commencing trading on the Nasdaq Capital Market on August 15, 2025. The gross proceeds of $4 million, before deducting underwriting discounts and expenses, will support Propanc's novel therapeutic approach.

Propanc's technology represents a groundbreaking approach to cancer treatment by utilizing pancreatic proenzymes that specifically target and eradicate cancer stem cells. These stem cells are responsible for tumor recurrence and metastasis, making them a critical focus in oncology research. The company's therapy is based on the scientific premise that pancreatic enzymes serve as the body's primary defense mechanism against cancer development and progression.

The successful funding round comes at a crucial time for cancer drug development, particularly for solid tumors that have proven resistant to conventional treatments. The ability to secure $4 million in public market funding demonstrates investor confidence in Propanc's scientific approach and its potential to address unmet medical needs in oncology. For more information about the company's research and development efforts, visit https://www.propanc.com.

This financing enables Propanc to advance its clinical programs and potentially accelerate the development timeline for its proenzyme therapy. The treatment approach could offer new hope for patients with aggressive cancers known for high recurrence rates, particularly pancreatic cancer which has historically shown limited treatment options and poor survival rates. The company's focus on targeting cancer stem cells aligns with emerging trends in precision oncology that seek to address the root causes of tumor persistence and spread.

The public offering's success reflects growing investor interest in innovative biotechnologies that target fundamental cancer mechanisms. As Propanc moves forward with its clinical development, this funding provides essential resources for conducting necessary research and potentially bringing new treatment options to patients facing some of the most challenging cancer diagnoses. Additional details about the offering can be found at https://ibn.fm/QxpyL.